Page 53 - GTM-3-1

Global Translational Medicine Personalized, multi-omics disease detection

doi: 10.1016/j.bios.2023.115103 doi: 10.7490/f1000research.1119646.1
64. Ma YL, Ke JF, Wang JW, Wang YJ, Xu MR, Li LX. Blood 76. Medicine IoMURoE-B. 6, Missed Prevention Opportunities.
lactate levels are associated with an increased risk of In: Yong PL, Olsen LA, editors. The Healthcare Imperative:
metabolic dysfunction-associated fatty liver disease in type 2 Lowering Costs and Improving Outcomes: Workshop Series
diabetes: A real-world study. Front Endocrinol (Lausanne). Summary. Washington, D.C: National Academies Press; 2010.
2023;14:1133991.
77. Dhingra LS, Aminorroaya A, Oikonomou EK, et al. Use
doi: 10.3389/fendo.2023.1133991 of wearable devices in individuals with or at risk for
cardiovascular disease in the US, 2019 to 2020. JAMA Netw
65. Liu F, Lu JX, Tang JL, et al. Relationship of plasma creatinine
and lactic acid in type 2 diabetic patients without renal Open. 2023;6(6):e2316634.
dysfunction. Chin Med J (Engl). 2009;122(21):2547-2553. doi: 10.1001/jamanetworkopen.2023.16634
66. (FDA) USFaDA. ECG App Classified into Class II-FDA. 78. Roche. Technical Specifications-FoundationOne®CDx
Cupertino: Apple Inc.; 2018. Available from: https://www. (F1CDx); 2023. Available from: https://assets.ctfassets.
accessdata.fda.gov/cdrh_docs/pdf18/den180044.pdf [Last net/w98cd481qyp0/yqqkhaqqmfeqc5ueqk48w/
accessed on 2024 Mar 20]. d12f19680205941ea3fee417f08e9524/f1cdx_technical_
specifications.pdf [Last accessed on 2024 Mar 20].
67. Smith S. Which Smartwatch is FDA Approved?;
2023. Available from: https://isp.page/news/which- 79. Mundt F. Nielsen, AB, Duel JK, et al. In depth profiling of the
smartwatch-is-fda-approved/#gsc.tab=0 [Last accessed cancer proteome from the flowthrough of standard RNA-
on 2023 Nov 30]. preparation kits for precision oncology. bioRxiv [Perprint]. 2023.
68. FDA.Report. Omron Heart Guide Wrist Blood Pressure doi: 10.1101/2023.05.12.540582
Monitor, Large BP8000-L. Available from: https://fda.report/ 80. Doll S, Kriegmair MC, Santos A, et al. Rapid proteomic
GUDID/20073796268026 [Last accessed on 2024 Mar 20].
analysis for solid tumors reveals LSD1 as a drug target in an
69. Mason AE, Hecht FM, Davis SK, et al. Detection of COVID- end-stage cancer patient. Mol Oncol. 2018;12(8):1296-1307.
19 using multimodal data from a wearable device: Results doi: 10.1002/1878-0261.12326
from the first TemPredict Study. Sci Rep. 2022;12(1):3463.
81. Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics
doi: 10.1038/s41598-022-07314-0
profiling reveals dynamic molecular and medical
70. Cheong SHR, Ng YJX, Lau Y, Lau ST. Wearable technology phenotypes. Cell. 2012;148(6):1293-1307.
for early detection of COVID-19: A systematic scoping doi: 10.1016/j.cell.2012.02.009
review. Prev Med. 2022;162:107170.
82. Li X, Dunn J, Salins D, et al. Digital health: Tracking physiomes
doi: 10.1016/j.ypmed.2022.107170
and activity using wearable biosensors reveals useful health-
71. Messner CB, Demichev V, Wendisch D, et al. Ultra-high- related information. PLoS Biol. 2017;15(1):e2001402.
throughput clinical proteomics reveals classifiers of COVID- doi: 10.1371/journal.pbio.2001402
19 infection. Cell Syst. 2020;11(1):11-24.e4.
83. Schussler-Fiorenza Rose SM, Contrepois K, Moneghetti KJ,
doi: 10.1016/j.cels.2020.05.012
et al. A longitudinal big data approach for precision health.
72. Vayena E, Blasimme A, Sugarman J. Decentralised clinical Nat Med. 2019;25(5):792-804.
trials: Ethical opportunities and challenges. Lancet Digit doi: 10.1038/s41591-019-0414-6
Health. 2023;5(6):e390-e394.
84. Shen X, Kellogg R, Panyard DJ, et al. Multi-omics
doi: 10.1016/S2589-7500(23)00052-3
microsampling for the profiling of lifestyle-associated
73. Porsdam Mann S, Treit PV, Geyer PE, Omenn GS, Mann M. changes in health. Nat Biomed Eng. 2023;8:11-29.
Ethical principles, opportunities and constraints in clinical doi: 10.1038/s41551-022-00999-8
proteomics. Mol Cell Proteomics. 2021;20:100046.
85. (FDA) USFaDA. Use of Electronic Informed Consent in Clinical
doi: 10.1074/mcp.RA120.002435
Investigations–Questions and Answers; 2023. Available from:
74. Caufield JH, Fu J, Wang D, Guevara-Gonzalez V, Wang W, https://www.fda.gov/regulatory-information/search-fda-
Ping P. A Second look at FAIR in proteomic investigations. guidance-documents/use-electronic-informed-consent-
J Proteome Res. 2021;20(5):2182-2186. clinical-investigations-questions-and-answers [Last
accessed on 2024 Mar 20].
doi: 10.1021/acs.jproteome.1c00177
86. Sharma S, Efird JT, Knupp C, et al. Sleep disorders in adult
75. Giannattasio S, Heil KF, Hermjakob H, et al. The next
challenge: Data management, submission and FAIRness in sickle cell patients. J Clin Sleep Med. 2015;11(3):219-223.
multi-omics experiments. F1000Res. 2023;12:1379. doi: 10.5664/jcsm.4530

Volume 3 Issue 1 (2024) 13 https://doi.org/10.36922/gtm.2357